



# Aldatu Biosciences



**Contact:**  
David Raiser, Ph.D.

**Location:**  
Cambridge, MA

**Email:**  
change@aldatubio.com

**Tel:**  
978.705.1036

**Website:**  
http://www.aldatubio.com



## Company Profile

**Industry Sector:** Diagnostics, Reagents

**Company Overview:** Aldatu Biosciences is a biotechnology company developing innovative diagnostic tools based on its proprietary genotyping platform, PANDAA. Aldatu is committed to commercializing products that address diagnostic challenges in global health, primarily in HIV and other infectious diseases.

**Initial Target Market(s):** Governments and Ministries of Health in low- and middle-income countries (LMICs) with high HIV burden.



## Key Value Drivers

**Technology:** Aldatu's Pan-Degenerate Amplification and Adaptation (PANDAA) platform technology overcomes genotyping challenges associated with HIV biology and enables qPCR for drug resistance testing for the first time, facilitating development of affordable and sensitive diagnostic tools to meet this growing unmet clinical need.

**Competitive Advantage:** PANDAA is a simple, rapid, highly sensitive, and low-cost alternative to existing Sanger sequencing-based genotyping tests and pipeline NGS-based solutions. Point mutation assay approach enables focused genotyping and cost-efficient test design.

**Plan & Strategy:** Optimize thermostable HIV drug resistance test prototype for pilot testing in sub-Saharan Africa, partner with global Dx companies and NGOs for scale-up and implementation.



## Management

### Leadership:

David Raiser, Ph.D. – Chief Executive Officer  
Iain MacLeod, LL.M., Ph.D. – Chief Science Officer

### Scientific Advisory Board:

Mickey Urdea, Ph.D. – SAB Member  
Mark Wainberg, Ph.D. – SAB Member  
Christopher Rowley, M.D., M.P.H. – Clinical Advisor  
Bill Rodriguez, M.D. – Commercialization Advisor



## Product Development

**1. Current Development:** Aldatu's lead product, PANDAA HIV6, will be the first HIV drug resistance test designed specifically to meet the clinical and economic constraints of sub-Saharan Africa, offering compelling healthcare cost savings opportunities and improving patient outcomes.

**2. Future Development:** The Aldatu HIV product line will expand to include tests that serve additional patient populations with distinct genotyping needs (e.g. US/Europe), and PANDAA will also be translated to a point-of-care platform. As the PANDAA platform is highly customizable, Aldatu plans to develop tests for genotyping and pathogen detection applications across a broad range of infections and disease areas.